Clinuvel Pharmaceuticals Ltd has released a press release.
CUV103 Singaporean Phase II vitiligo study results
Filed with ASX ·
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- Appeal Upheld Against NICE Recommendation in England
- S&P DJI Announces September 2018 Quarterly Rebalance
- US FDA Update
- CLINUVEL completes SCENESSE FDA Filing
- NICE maintains position not to recommend SCENESSE
Later from Clinuvel Pharmaceuticals
- US FDA sets PDUFA date for SCENESSE
- US FDA extends PDUFA date for SCENESSE
- CLINUVEL declares Full Year Dividend
- Appendix 4E and Preliminary Financial Report Reissued
- Dividend/Distribution - CUV
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals